Geoffrey Ku
杰弗里·库
MD
Associate Attending Physician, Gastrointestinal Oncology Service胃肠肿瘤服务副主任医师
👥Biography 个人简介
Dr. Geoffrey Ku at MSKCC specializes in esophageal and gastroesophageal junction cancers. He has been instrumental in trials evaluating nivolumab and HER2-directed therapies, helping define first-line immunotherapy standards for esophageal squamous cell carcinoma and adenocarcinoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Nivolumab in Esophageal Cancer
Key contributor to CheckMate 648 trial establishing nivolumab plus chemotherapy or ipilimumab as a first-line standard for esophageal squamous cell carcinoma globally.
HER2-Targeted Therapy
Investigated HER2-directed agents in esophageal and GEJ adenocarcinoma, helping define biomarker selection strategies for HER2-positive upper GI cancers.
Representative Works 代表性著作
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (CheckMate 648)
Journal of Clinical Oncology (2022)
Established dual-immunotherapy and chemo-immunotherapy combinations as new first-line standards for esophageal squamous cell carcinoma.
A phase II study of 2-week oxaliplatin, fluorouracil, and leucovorin (FOLFOX) as first-line chemotherapy in patients with advanced esophageal cancer
Cancer (2012)
Demonstrated FOLFOX efficacy and tolerability in advanced esophageal cancer, informing subsequent combination regimen development.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 杰弗里·库 的研究动态
Follow Geoffrey Ku's research updates
留下邮箱，当我们发布与 Geoffrey Ku（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment